MARTHA AKINBILE: Open Payments
NPI 1164943403 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,585 in 58 payments from 12 companies in 2025. Trend: 2023 $850 · 2024 $586 · 2025 $1,585
Food & beverage: $1,569Education: $16
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $494 |
| ABBVIE INC. | 16 | $334 |
| Alkermes, Inc. | 6 | $179 |
| Vanda Pharmaceuticals Inc. | 7 | $136 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $87 |
| Almatica Pharma LLC | 2 | $57 |
| Neurocrine BioSciences, Inc. | 2 | $52 |
| Janssen Pharmaceuticals, Inc | 1 | $30 |
| E.R. Squibb & Sons, L.L.C. | 1 | $30 |
Products named: VRAYLAR, REXULTI, ARISTADA, FANAPT, CAPLYTA, ABILIFY MAINTENA, ABILIFY ASIMTUFII, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
